JN0642 重组人含表皮生长因子样重复区和盘

我公司致力于为客户提供高纯度、低成本的活性重组蛋白，包括重组人含表皮生长因子样重复区和盘在内的各类受体、细胞因子、生长因子、转录因子、激素、酶、毒性蛋白、病毒抗原等。

北京百奥莱博科技有限公司是一家专业的生物试剂销售公司。公司主要经营血清、抗原、抗体等生物试剂产品，可以为您提供专业的技术服务，以优良的价格、优质的服务、优先的理念，满足客户的各方面的需求，与国内多家企业、单位建立了良好的长期合作关系，拥有较好的企业信誉和品牌形象。 主营产品:血清、抗体、抗原、核酸提取、核酸纯化等生化试剂

特别提示：包括重组人含表皮生长因子样重复区和盘状结构域1的蛋白3(EDIL3)在内，本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！

产品名称：重组人含表皮生长因子样重复区和盘状结构域1的蛋白3(EDIL3)
英文名称：Recombinant Human EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3
产品货号：JN0642
产品规格：10μg|50μg|500μg|1mg

本品由我们的哺乳动物细胞表达系统制备而成，目的基因编码的Val17-Glu480在C端含有His标签。

EDIL3质量控制：＞95%(还原性SDS-PAGE)

EDIL3制剂：冻干品

EDIL3保存：
冻干蛋白置于-20℃以下可长期保存，室温条件下可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天，可分装后置于-20℃保存三个月。

EDIL3复溶：
打开试剂管前请先离心。
复溶浓度推荐大于100 μg/ml。
冻干蛋白请溶于ddH2O。
复溶后，请根据用量分装冻存，避免反复冻融。

关于EDIL3：
EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3 (EDIL3) is a 52 kDa extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development. EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. EDIL3 has been found to be re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis. EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through upregulation of Bcl-2 expression. EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA-1-dependent leukocyte-endothelial adhesion. Human EDIL3 is synthesized as a precursor with a 16 amino acid signal sequence and a 464 amino acid mature chain.

根据您的关注的重组人含表皮生长因子样重复区和盘状结构域1的蛋白3(EDIL3)，重组人含表皮生长因子样重复区和盘状结构域1的蛋白3(EDIL3)，rhEDIL3，EDIL3，重组人EDIL3，重组EDIL3，rEDIL3，重组人含表皮生长因子样重复区和盘状结构域1的蛋白3，重组人EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，重组EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，Recombinant Human EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，重组含表皮生长因子样重复区和盘状结构域1的蛋白3，JN0642，百奥莱博，，，您可能还对以下产品有需求：


JN0228 重组人酸性FGF1(成纤维细胞生长因子1) 10μg|50μg|500μg|1mg
JN0409 重组人白介素IL-2Rγ(白细胞介素2Rγ) 10μg|50μg|500μg|1mg
JN0457 重组人肿瘤坏死因子受体超家族成员12A(TNFRSF12A) 10μg|50μg|500μg|1mg
JN0460 重组人Fas(TNFRSF6)(CD95) 10μg|50μg|500μg|1mg
JN2028 重组人S100-P蛋白 10μg|50μg|500μg|1mg
JN0514 重组人碳酸酐酶10(CA10) 10μg|50μg|500μg|1mg
JN0596 重组人神经营养酪氨酸激酶受体2型(NTRK2) 10μg|50μg|500μg|1mg

关注重组人含表皮生长因子样重复区和盘状结构域1的蛋白3(EDIL3)，重组人含表皮生长因子样重复区和盘状结构域1的蛋白3(EDIL3)，rhEDIL3，EDIL3，重组人EDIL3，重组EDIL3，rEDIL3，重组人含表皮生长因子样重复区和盘状结构域1的蛋白3，重组人EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，重组EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，Recombinant Human EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，重组含表皮生长因子样重复区和盘状结构域1的蛋白3，JN0642，百奥莱博，，的同时，为您推荐更多您可能感兴趣的产品：



名称：重组人趋化因子CXCL2(MIP-2)
货号：JN0298
规格：10μg|50μg|500μg|1mg
本品由我们的大肠杆菌表达系统制备，目的基因编码的Thr39-Asn107表达纯化而来。

CXCL2/MIP-2质量控制：＞95%(还原性SDS-PAGE)。

CXCL2/MIP-2制剂：冻干品

CXCL2/MIP-2保存：
冻干蛋白可在-20℃长期保存，室温也可稳定保存3周。
复溶蛋白溶液可在4～7℃保存2～7天。
复溶后建议分装冻存在-20℃，可保存3个月，应避免反复冻融。

CXCL2/MIP-2复溶：
1、试剂开盖前请先离心。
2、复溶浓度应大于100 μg/ml.
3、冻干蛋白溶于ddH2O中
4、复溶后根据使用量分装保存，避免反复冻融。

关于CXCL2/MIP-2：
Chemokine Ligand 2 (CXCL2) is a small secreted cytokine which belongs to the CXC chemokine family. It is secreted by monocytes and macrophages and chemotactic for polymorphonuclear leukocytes and hematopoietic stem cells. CXCL2 mobilizes cells by interacting with a cell surface chemokine receptor called CXCR2. It has been known to regulate immune functions mainly by chemo-attracting neutrophils. It is produced by activated monocytes and neutrophils and expressed at sites of inflammation. It is a hematoregulatory chemokine, which suppresses hematopoietic progenitor cell proliferation. It can be induced by receptor activator of NF-kappaB ligand, the osteoclast (OC) differentiation factor, through JNK and NF-kappaB signaling pathways in OC precursor cells. CXCL2 in turn enhanced the proliferation of OC precursor cells of bone marrow-derived macrophages (BMMs) through the activation of ERK. Knockdown of CXCL2 inhibited both the proliferation of and the ERK activation in BMMs. During osteoclastogenesis CXCL2 stimulated the adhesion and the migration of BMMs. CXCL2 is a novel therapeutic target for inflammatory bone destructive diseases.

本页产品地址：http://www.geilan.com/sell/show-8529010.html